Review of ATRA and ATO induction therapy in acute promyelocytic leukemia with RNA sequencing insights

This source is a case report and literature review focusing on induction therapy with all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia. The narrative centers on a single 34-year-old man who underwent this treatment regimen. The primary outcome of interest was the achievement of complete molecular remission, which was reported as achieved in this specific case. A secondary outcome tracked was molecular relapse, which occurred in this patient.

The patient underwent premature discontinuation of maintenance therapy, and molecular relapse was observed three months after this discontinuation. The review notes that adverse events and serious adverse events were not reported, and tolerability was not reported. The authors do not provide pooled effect sizes or absolute numbers for the outcomes, as the primary data source is a single case report rather than a meta-analysis of multiple trials.

The authors suggest that the findings highlight the potential value of incorporating RNA sequencing into the diagnostic workflow for morphologically suspected but PCR-negative acute promyelocytic leukemia. This approach may assist in identifying cases where standard PCR methods might be negative. The certainty of these conclusions is limited by the small sample size and the lack of reported safety data.

Clinicians should interpret these findings with caution, recognizing that the evidence is derived from a single case and a literature review rather than a randomized controlled trial. The practice relevance is framed around diagnostic utility rather than definitive treatment efficacy or safety profiles.